Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Association of habitual physical activity measured by an accelerometer with high-density lipoprotein cholesterol levels in maintenance hemodialysis patients.

Matsuzawa R, Matsunaga A, Kutsuna T, Ishii A, Abe Y, Yoneki K, Harada M, Ishibashi M, Takeuchi Y, Yoshida A, Takahira N.

ScientificWorldJournal. 2013 Dec 21;2013:780783. doi: 10.1155/2013/780783.

2.

Serum non-high-density lipoprotein cholesterol (non-HDL-C) levels and cardiovascular mortality in chronic hemodialysis patients.

Echida Y, Ogawa T, Otsuka K, Ando Y, Nitta K.

Clin Exp Nephrol. 2012 Oct;16(5):767-72. doi: 10.1007/s10157-012-0615-5.

PMID:
22374049
3.

Habitual physical activity measured by accelerometer and survival in maintenance hemodialysis patients.

Matsuzawa R, Matsunaga A, Wang G, Kutsuna T, Ishii A, Abe Y, Takagi Y, Yoshida A, Takahira N.

Clin J Am Soc Nephrol. 2012 Dec;7(12):2010-6. doi: 10.2215/CJN.03660412.

4.

Low-density lipoprotein cholesterol: association with mortality and hospitalization in hemodialysis patients.

Chiang CK, Ho TI, Hsu SP, Peng YS, Pai MF, Yang SY, Hung KY, Tsai TJ.

Blood Purif. 2005;23(2):134-40.

PMID:
15665509
5.

Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients.

Honda H, Ueda M, Kojima S, Mashiba S, Michihata T, Takahashi K, Shishido K, Akizawa T.

Atherosclerosis. 2012 Feb;220(2):493-501. doi: 10.1016/j.atherosclerosis.2011.10.038.

PMID:
22119537
6.

The uremic dyslipidemia: a cross-sectional and longitudinal study.

Avram MM, Goldwasser P, Burrell DE, Antignani A, Fein PA, Mittman N.

Am J Kidney Dis. 1992 Oct;20(4):324-35.

PMID:
1415199
7.

Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease.

Nishizawa Y, Shoji T, Kakiya R, Tsujimoto Y, Tabata T, Ishimura E, Nakatani T, Miki T, Inaba M.

Kidney Int Suppl. 2003 May;(84):S117-20. Erratum in: Kidney Int Suppl. 2003 Jun;63(6):2345-6.

PMID:
12694324
8.

Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.

Grover SA, Kaouache M, Joseph L, Barter P, Davignon J.

Arch Intern Med. 2009 Oct 26;169(19):1775-80. doi: 10.1001/archinternmed.2009.328.

PMID:
19858435
9.

Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.

Navarro JF, Mora C, Muros M, García-Idoate G.

Nephron Clin Pract. 2003;95(4):c128-35.

PMID:
14694274
10.

Increased lipoprotein (a) and its relationships with other parameters of lipoprotein metabolism in chronic renal failure treated by hemodialysis.

Yiğitoğlu MR, Polat MF, Akçay F, Ari Z, Uyanik BS, Ozilgili HM.

Jpn Heart J. 1997 Jan;38(1):83-9.

PMID:
9186284
11.

Nonfasting non-high-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients.

Desmeules S, Arcand-Bossé JF, Bergeron J, Douville P, Agharazii M.

Am J Kidney Dis. 2005 Jun;45(6):1067-72.

PMID:
15957136
12.

Low body mass index and dyslipidemia in dialysis patients linked to elevated plasma fibroblast growth factor 23.

Montford JR, Chonchol M, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Kendrick J; HOST Investigators..

Am J Nephrol. 2013;37(3):183-90. doi: 10.1159/000346941.

13.

Association of Adiponectin With Body Composition and Mortality in Hemodialysis Patients.

Rhee CM, Nguyen DV, Moradi H, Brunelli SM, Dukkipati R, Jing J, Nakata T, Kovesdy CP, Brent GA, Kalantar-Zadeh K.

Am J Kidney Dis. 2015 Aug;66(2):313-21. doi: 10.1053/j.ajkd.2015.02.325.

14.

Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients.

Shoji T, Masakane I, Watanabe Y, Iseki K, Tsubakihara Y; Committee of Renal Data Registry, Japanese Society for Dialysis Therapy..

Clin J Am Soc Nephrol. 2011 May;6(5):1112-20. doi: 10.2215/CJN.09961110.

15.

What factors accelerate aortic stiffening in hemodialysis patients? An observational study.

Matsumae T, Ueda K, Abe Y, Nishimura S, Murakami G, Saito T.

Hypertens Res. 2010 Mar;33(3):243-9. doi: 10.1038/hr.2009.219.

PMID:
20075931
16.

Anti-inflammatory properties of high-density lipoprotein cholesterol in chronic hemodialysis patients: impact of intervention.

Mistrík E, Bláha V, Dusilová-Sulková S, Andrýs C, Kalousová M, Sobotka L.

J Ren Nutr. 2010 Nov;20(6):368-76. doi: 10.1053/j.jrn.2010.07.003.

PMID:
20833077
17.

Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study.

Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, Dworkin L, Rosenberg IH.

Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2554-8.

18.

Reverse epidemiology of lipid-death associations in a cohort of end-stage renal disease patients.

Bowden RG, La Bounty P, Shelmadine B, Beaujean AA, Wilson RL, Hebert S.

Nephron Clin Pract. 2011;119(3):c214-9. doi: 10.1159/000329509.

PMID:
21832847
19.

The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.

Pennell P, Leclercq B, Delahunty MI, Walters BA.

Clin Nephrol. 2006 Nov;66(5):336-47.

PMID:
17140163
20.
Items per page

Supplemental Content

Support Center